| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 545 | 2018 |
| Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia M Ilander, U Olsson-Strömberg, H Schlums, J Guilhot, O Brück, ... Leukemia 31 (5), 1108-1116, 2017 | 242 | 2017 |
| Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome J Richter, S Söderlund, A Lübking, A Dreimane, K Lotfi, B Markevärn, ... J Clin Oncol 32 (25), 2821-2823, 2014 | 150 | 2014 |
| Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C B Ingelsson, D Söderberg, T Strid, A Söderberg, AC Bergh, V Loitto, ... Proceedings of the National Academy of Sciences 115 (3), E478-E487, 2018 | 124 | 2018 |
| Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells K Lotfi, E Månsson, T Spasokoukotskaja, B Pettersson, J Liliemark, ... Clinical cancer research 5 (9), 2438-2444, 1999 | 116 | 1999 |
| First-line venetoclax combinations in chronic lymphocytic leukemia B Eichhorst, CU Niemann, AP Kater, M Fürstenau, J Von Tresckow, ... New England Journal of Medicine 388 (19), 1739-1754, 2023 | 94 | 2023 |
| Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance K Lotfi, AL Zackrisson, C Peterson Cancer letters 178 (2), 141-149, 2002 | 75 | 2002 |
| Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (N ord CML 006) H Hjorth‐Hansen, L Stenke, S Söderlund, A Dreimane, H Ehrencrona, ... European journal of haematology 94 (3), 243-250, 2015 | 74 | 2015 |
| Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype H Green, IJ Falk, K Lotfi, E Paul, M Hermansson, R Rosenquist, C Paul, ... The pharmacogenomics journal 12 (2), 111-118, 2012 | 66 | 2012 |
| Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia K Willander, IJ Falk, R Chaireti, E Paul, M Hermansson, H Gréen, K Lotfi, ... Biomarker research 2, 1-9, 2014 | 56 | 2014 |
| Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis MA Mosrati, K Willander, IJ Falk, M Hermanson, M Höglund, ... Oncotarget 6 (28), 25109, 2015 | 51 | 2015 |
| A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up U Frödin, S Börjeson, J Lyth, K Lotfi Bone marrow transplantation 46 (10), 1345-1352, 2011 | 51 | 2011 |
| CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity H Gréen, K Skoglund, F Rommel, RA Mirghani, K Lotfi European journal of clinical pharmacology 66, 383-386, 2010 | 50 | 2010 |
| A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic … B Eichhorst, C Niemann, AP Kater, M Fürstenau, J Von Tresckow, ... Blood 138, 71, 2021 | 48 | 2021 |
| Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide K Lotfi, E Månsson, J Chandra, Y Wang, D Xu, E Knaust, ... British journal of haematology 113 (2), 339-346, 2001 | 48 | 2001 |
| Pharmacological basis for cladribine resistance K Lotfi, G Juliusson, F Albertioni Leukemia & lymphoma 44 (10), 1705-1712, 2003 | 44 | 2003 |
| Decreased survival in normal karyotype AML with single‐nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′‐nucleotidase IJ Falk, A Fyrberg, E Paul, H Nahi, M Hermanson, R Rosenquist, ... American journal of hematology 88 (12), 1001-1006, 2013 | 38 | 2013 |
| Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-β-D-arabinofuranosylguanine cytotoxicity K Lotfi, E Månsson, C Peterson, S Eriksson, F Albertioni Biochemical and biophysical research communications 293 (5), 1489-1496, 2002 | 33 | 2002 |
| Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death JR Jangamreddy, MV Jain, AL Hallbeck, K Roberg, K Lotfi, MJ Łos Oncotarget 6 (12), 10134, 2015 | 30 | 2015 |
| The pattern of deoxycytidine-and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic … K Lotfi, K Karlsson, A Fyrberg, G Juliusson, V Jonsson, C Peterson, ... Biochemical pharmacology 71 (6), 882-890, 2006 | 30 | 2006 |
